Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE is a synthetic peptide or peptidomimetic characterized by its complex chemical structure, which includes a guanidinomethyl-cyclohexane moiety, D-cyclohexylalanyl, L-azetidine-2-yl, D-tyrosinyl, and L-homoargininamide residues. The presence of guanidinium groups (from guanidinomethyl and homoargininamide) suggests potential interactions with negatively charged biological sites, often found in enzyme active sites or receptor binding pockets. The L-azetidine-2-yl residue is a proline analog, which can introduce conformational constraints and influence the secondary structure and stability of the peptide, thereby affecting its biological activity and interaction with target molecules. While the specific biological activity, primary indication, or developer of this compound are not readily available in public databases, its intricate design is typical of compounds developed for research into protein-ligand interactions, enzyme inhibition, or receptor modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE.